Abstract

This study compared all-cause adverse event (ACAE) cost per patient of nivolumab + ipilimumab + limited chemotherapy (N+I+C) vs. chemotherapy (C), pembrolizumab + chemotherapy (P+C), and atezolizumab + chemotherapy (A+C) as first-line therapy for Stage IV or recurrent non-small-cell lung cancer.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.